proto labs inc. - PRLB
PRLB
Close Chg Chg %
39.78 1.72 4.32%
Closed Market
41.50
+1.72 (4.32%)
Volume: 442.54K
Last Updated:
Nov 22, 2024, 3:59 PM EDT
Company Overview: proto labs inc. - PRLB
PRLB Key Data
| Open $40.00 | Day Range 39.79 - 41.65 |
| 52 Week Range 25.76 - 41.87 | Market Cap $974.03M |
| Shares Outstanding 24.51M | Public Float 24.20M |
| Beta 1.32 | Rev. Per Employee N/A |
| P/E Ratio 42.25 | EPS $0.94 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 352.59K |
PRLB Performance
| 1 Week | 6.06% | ||
| 1 Month | 48.78% | ||
| 3 Months | 29.78% | ||
| 1 Year | 7.12% | ||
| 5 Years | -58.85% |
PRLB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About proto labs inc. - PRLB
Proto Labs, Inc. engages in the manufacture of custom prototypes and production parts. It offers 3D printing, CNC machining, and injection molding services. It operates through the following segments: United States, Europe, and Japan. The company was founded by Lawrence J. Lukis and Gregg Bloom on May 5, 1999, and is headquartered in Maple Plain, MN.
PRLB At a Glance
Proto Labs, Inc.
5540 Pioneer Creek Drive
Maple Plain, Minnesota 55359
| Phone | 1-763-479-3680 | Revenue | 503.88M | |
| Industry | Chemicals: Specialty | Net Income | 17.22M | |
| Sector | Process Industries | 2023 Sales Growth | 3.169% | |
| Fiscal Year-end | 12 / 2024 | Employees | 2,415 | |
| View SEC Filings |
PRLB Valuation
| P/E Current | 41.733 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 59.327 |
| Price to Sales Ratio | 2.028 |
| Price to Book Ratio | 1.441 |
| Price to Cash Flow Ratio | 13.943 |
| Enterprise Value to EBITDA | 14.024 |
| Enterprise Value to Sales | 1.834 |
| Total Debt to Enterprise Value | 0.006 |
PRLB Efficiency
| Revenue/Employee | 208,644.72 |
| Income Per Employee | 7,130.435 |
| Receivables Turnover | 6.712 |
| Total Asset Turnover | 0.631 |
PRLB Liquidity
| Current Ratio | 4.039 |
| Quick Ratio | 3.764 |
| Cash Ratio | 2.069 |
PRLB Profitability
| Gross Margin | 44.057 |
| Operating Margin | 5.633 |
| Pretax Margin | 5.547 |
| Net Margin | 3.418 |
| Return on Assets | 2.155 |
| Return on Equity | 2.472 |
| Return on Total Capital | 2.457 |
| Return on Invested Capital | 2.462 |
PRLB Capital Structure
| Total Debt to Total Equity | 0.789 |
| Total Debt to Total Capital | 0.783 |
| Total Debt to Total Assets | 0.689 |
| Long-Term Debt to Equity | 0.518 |
| Long-Term Debt to Total Capital | 0.514 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Proto Labs Inc. - PRLB
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 434.39M | 488.10M | 488.40M | 503.88M | |
Sales Growth
| -5.30% | +12.36% | +0.06% | +3.17% | |
Cost of Goods Sold (COGS) incl D&A
| 216.57M | 265.41M | 272.93M | 281.88M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 32.59M | 40.49M | 39.42M | 37.53M | |
Depreciation
| 29.59M | 34.29M | 33.42M | 31.63M | |
Amortization of Intangibles
| 3.00M | 6.20M | 6.00M | 5.90M | |
COGS Growth
| -3.07% | +22.55% | +2.84% | +3.28% | |
Gross Income
| 217.83M | 222.69M | 215.47M | 221.99M | |
Gross Income Growth
| -7.42% | +2.23% | -3.24% | +3.03% | |
Gross Profit Margin
| +50.14% | +45.62% | +44.12% | +44.06% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 157.99M | 194.85M | 188.52M | 193.61M | |
Research & Development
| 36.94M | 44.24M | 38.22M | 40.13M | |
Other SG&A
| 121.05M | 150.61M | 150.30M | 153.48M | |
SGA Growth
| +1.65% | +23.33% | -3.25% | +2.70% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (12.50M) | 124.93M | 215.00K | |
EBIT after Unusual Expense
| 59.84M | 40.34M | (97.98M) | 28.17M | |
Non Operating Income/Expense
| 3.11M | (158.00K) | 106.00K | 885.00K | |
Non-Operating Interest Income
| 1.40M | 200.00K | 1.00M | 3.30M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 1.10M | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | 1.10M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 62.95M | 40.18M | (97.88M) | 27.95M | |
Pretax Income Growth
| -22.47% | -36.16% | -343.57% | +128.56% | |
Pretax Margin
| +14.49% | +8.23% | -20.04% | +5.55% | |
Income Tax
| 12.08M | 6.81M | 5.58M | 10.73M | |
Income Tax - Current - Domestic
| 4.15M | 9.25M | 20.21M | 17.91M | |
Income Tax - Current - Foreign
| 1.24M | (64.00K) | (99.00K) | 34.00K | |
Income Tax - Deferred - Domestic
| 6.47M | (1.19M) | (9.88M) | (8.59M) | |
Income Tax - Deferred - Foreign
| 210.00K | (1.18M) | (4.64M) | 1.38M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 50.87M | 33.37M | (103.46M) | 17.22M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 50.87M | 33.37M | (103.46M) | 17.22M | |
Net Income Growth
| -20.09% | -34.39% | -410.03% | +116.64% | |
Net Margin Growth
| +11.71% | +6.84% | -21.18% | +3.42% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 50.87M | 33.37M | (103.46M) | 17.22M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 50.87M | 33.37M | (103.46M) | 17.22M | |
EPS (Basic)
| 1.9025 | 1.2084 | -3.7746 | 0.6576 | |
EPS (Basic) Growth
| -19.70% | -36.48% | -412.36% | +117.42% | |
Basic Shares Outstanding
| 26.74M | 27.62M | 27.41M | 26.19M | |
EPS (Diluted)
| 1.8912 | 1.2068 | -3.7746 | 0.6567 | |
EPS (Diluted) Growth
| -19.64% | -36.19% | -412.78% | +117.40% | |
Diluted Shares Outstanding
| 26.90M | 27.65M | 27.41M | 26.22M | |
EBITDA
| 92.43M | 68.33M | 66.37M | 65.91M | |
EBITDA Growth
| -16.52% | -26.08% | -2.86% | -0.70% | |
EBITDA Margin
| +21.28% | +14.00% | +13.59% | +13.08% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 38.333 | |
| Number of Ratings | 5 | Current Quarters Estimate | 0.32 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 1.572 | |
| Last Quarter’s Earnings | 0.47 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.59 | Next Fiscal Year Estimate | 1.50 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 4 | 5 | 4 |
| Mean Estimate | 0.32 | 0.34 | 1.57 | 1.50 |
| High Estimates | 0.34 | 0.37 | 1.59 | 1.58 |
| Low Estimate | 0.29 | 0.32 | 1.54 | 1.34 |
| Coefficient of Variance | 6.63 | 6.35 | 1.30 | 7.30 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Proto Labs Inc. - PRLB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Proto Labs Inc. - PRLB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 23, 2024 | Dan Schumacher Chief Financial Officer | 22,130 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $31.81 per share | 703,955.30 |
| May 23, 2024 | Michael R. Kenison VP and GM of the America s | 22,351 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $31.81 per share | 710,985.31 |
| Feb 16, 2024 | Robert Bodor President and CEO | 54,328 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.52 per share | 1,821,074.56 |
| Feb 16, 2024 | Robert Bodor President and CEO | 76,703 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Robert Bodor President and CEO | 41,209 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Bjoern Klaas VP and Mng Director-PL Europe | 16,333 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.52 per share | 547,482.16 |
| Feb 16, 2024 | Bjoern Klaas VP and Mng Director-PL Europe | 23,046 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Bjoern Klaas VP and Mng Director-PL Europe | 6,182 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Dan Schumacher Chief Financial Officer | 22,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Dan Schumacher Chief Financial Officer | 9,616 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Michael R. Kenison VP and GM of the America s | 22,405 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Michael R. Kenison VP and GM of the America s | 7,555 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Oleg Ryaboy Chief Technology Officer | 19,055 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.52 per share | 638,723.60 |
| Feb 16, 2024 | Oleg Ryaboy Chief Technology Officer | 29,497 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Oleg Ryaboy Chief Technology Officer | 9,616 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |